Concert Pharmaceuticals

Concert Pharmaceuticals (NASDAQ: CNCE) is a publicly-traded, clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.

In 2014, Concert raised an $84M IPO and began trading under the ticker symbol “CNCE.”


Company Profile

Concert Pharmaceuticals Logo

Flagship Partners:

  • Doug Cole, Managing Partner